UNITED STATES

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number: 000-30991

SKINOVATION PHARMACEUTICAL INCORPORATED

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

87-0458170

(I.R.S. Employer Identification No.)

2157 S. Lincoln Street, Salt Lake City, Utah

(Address of principal executive offices)

84106

(Zip Code)

(801) 323-2395

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]

Non-accelerated filer [ ]

Accelerated filer [ ]

Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [X] No [ ]

The number of shares outstanding of the registrant’s common stock as of November 1, 2012 was 708,000.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Balance Sheets

Condensed Statements of Operations

Condensed Statements of Cash Flows

Notes to the Unaudited Condensed Financial Statements

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Item 4. Controls and Procedures

PART II – OTHER INFORMATION

Item 6. Exhibits

Signatures

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SKINOVATION PHARMACEUTICAL INCORPORATED

(A Development Stage Company)

Financial Statements

September 30, 2012

(Unaudited)

Skinovation Pharmaceutical Incorporated

(A Development Stage Company)

Condensed Balance Sheets

The accompanying notes are an integral part of these financial statements

Skinovation Pharmaceutical Incorporated

(A Development Stage Company)

Notes to the Unaudited Condensed Financial Statements

September 30, 2012

NOTE 1 – CONDENSED FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended September 30, 2012 and for all periods presented have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2011 audited financial statements as reported in its Form 10-K. The results of operations for the nine month period ended September 30, 2012 are not necessarily indicative of the operating results for the full year ended December 31, 2012.

NOTE 2 – GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.

NOTE 3 - MATERIAL TRANSACTION

During the 2012 third quarter the Company invoiced and recorded non-recurring revenues of $40,977 USD related to business consulting services provided to a foreign third party.

NOTE 4 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

In this report references to “Skinovation,” “we,” “us,” and “our” refer to Skinovation Pharmaceutical Incorporated.

FORWARD LOOKING STATEMENTS

The U. S. Securities and Exchange Commission (“SEC”) encourages reporting companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions. This report contains these types of statements. Words such as “may,” “expect,” “believe,” “intend,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Executive Overview

We are a development stage company and we did not record revenues for the past two fiscal years; however, we have recorded non-recurring revenues of $40,977 from consulting services provided to another company during the three months ended September 30, 2012 (“2012 third quarter”). At September 30, 2012 we had $1,120 in cash and total liabilities of $104,375 and despite recent revenues we will likely remain dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company to generate revenue.

As of the date of this report, our management has not had any discussions with any representative of any other entity regarding a business combination with us. Any target business that is selected may be a financially unstable company or an entity in its early stages of development or growth, including entities without established records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially unstable and early stage or potential emerging growth companies. In addition, we may effect a business combination with an entity in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to present stockholders of the Company.

We anticipate that the selection of a business opportunity will be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available business combinations may occur in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex.

Management anticipates that the struggling global economy will restrict the cash available for business opportunities and will restrict the number of such transactions available to us. There can be no assurance in the current economy that we will be able to acquire an interest in an operating company.

If we obtain a business opportunity, then it may be necessary to raise additional capital. We anticipate that we will sell our common stock to raise this additional capital. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common stock.

Liquidity and Capital Resources

During the 2012 third quarter we recorded non-recurring revenues related to consulting services; however, prior to the 2012 third quarter we had not recorded revenues from operations since inception. Despite these revenues we have not established an ongoing source of revenue sufficient to cover our operating costs and we expect to rely upon third parties to pay for our operating expenses. As a result of revenues, at September 30, 2012 we had $1,120 in cash compared to $348 at December 31, 2011. Our total liabilities decreased to $104,375 at September 30, 2012 from $112,128 at December 31, 2011 primarily due to the payment of outstanding third party loans of approximately $35,000, which decreased our accounts payable.

We intend to obtain capital from management, significant stockholders and third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our profitability for the long term.

During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through advances and loans provided by management, significant stockholders or third parties. We may also rely on the issuance of our common stock in lieu of cash to convert debt or pay for expenses.

Results of Operations

During the 2011 third quarter we did not record revenues, nor did we record revenues in the nine month period ended September 30, 2011 (“2011 nine month period”). We recorded non-recurring revenues of $40,977 related to consulting services provided to another company during the 2012 third quarter and 2012 nine month period. General and administrative expense increased from $1,267 for the 2011 third quarter to $6,342 for the 2012 third quarter and increased from $4,954 for the 2011 nine month period to $26,953 for the 2012 nine month period. The increases in general and administrative expense in the 2012 nine month period primarily reflect $15,600 in consulting fees and administrative and professional services and other expenses paid on our behalf.

Total other expense decreased in the 2012 third quarter as compared to the 2011 third quarter as a result of decreased interest on outstanding loans which were paid. Total other expense increased in the 2012 nine month period compared to the 2011 nine month period due to the overall interest expense on loans.

Due to revenues in the 2012 third quarter, we recorded net income of $32,967 for the 2012 third quarter and net income of $8,525 for the 2012 nine month period. We recorded a net loss of $2,986 for the 2011 third quarter and a net loss of $10,116 for the 2011 nine month period. Despite the non-recurring revenues during the 2012 third quarter, management expects net losses to continue until we acquire or merge with a business opportunity.

Obligations

During the 2012 third quarter we paid $34,855 toward outstanding loans provided to us by a third party, reducing the outstanding amount to $3,871.

During the 2012 first quarter we borrowed $10,000 from third parties to fund our operations. These loans are unsecured, bear interest of 8% and are due upon demand.

At December 31, 2011 we had recorded current liabilities of $112,128 representing accounts payable to third parties and loans, along with accrued interest. Of this amount, $18,600 represented consulting services provided by a third party and $80,926 represented services received and cash advances received from unrelated parties as of December 31, 2010 which were converted to loans effective January 1, 2011. The loans are non-collateralized, carry interest at 8% and are due on demand.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and he determined that our disclosure controls and procedures were ineffective due to a control deficiency. During the period we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

Changes to Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an evaluation of our internal control over financial reporting and determined that there were no changes made in our internal control over financial reporting during the quarter ended September 30, 2012 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 6. EXHIBITS

Part I Exhibits


No.	Description
31.1	Principal Executive Officer Certification
31.2	Principal Financial Officer Certification
32.1	Section 1350 Certification

Part II Exhibits


No.	Description
3(i)	Articles of Incorporation, as amended (Incorporated by reference to exhibit 3.1 of Form 10-KSB, filed March 29, 2002)
3(ii)	Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of Form 10-SB, filed July 11, 2000)
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Label Linkbase Document
101.PRE	XBRL Taxonomy Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 14, 2012

SKINOVATION PHARMACEUTICAL INCORPORATED

By: /s/ Hugo Rodier

Hugo Rodier

President and Director

Principal Financial Officer



		SEPT 30, 2012		DEC 31, 2011
		(Unaudited)
ASSETS
Current Assets
Cash	$	1,120	$	348
Total Current Assets		1,120		348
Total Assets	$	1,120	$	348

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable	$	36,172	$	19,424
Loans		61,071		85,926
Accrued interest		7,132		6,778
Total Current Liabilities		104,375		112,128
Total Liabilities		104,375		112,128
Stockholders' Equity
Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding		0		0
Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding		708		708
Additional paid in capital		25,148		25,148
Deficit accumulated during the development stage		(129,111)		(137,636)
Total Stockholders' Equity		(103,255)		(111,780)
Total Liabilities and Stockholders' Equity	$	1,120	$	348



		FOR THE THREE MONTHS ENDED SEPT 30, 2012		FOR THE THREE MONTHS ENDED SEPT 30, 2011		FOR THE NINE MONTHS ENDED SEPT 30, 2012		FOR THE NINE MONTHS ENDED SEPT 30, 2011		FROM INCEPTION ON JAN 15, 1988 TO SEPT 30, 2012

REVENUES	$	40,977	$	0	$	40,977	$	0	$	40,977

EXPENSES
General and administrative		6,342		1,267		26,953		4,954		146,811
TOTAL EXPENSES		6,342		1,267		26,953		4,954		146,811

NET OPERATING INCOME (LOSS) BEFORE OTHER EXPENSE		34,635		(1,267)		14,024		(4,954)		(105,834)

OTHER INCOME (EXPENSE)
Interest expense		(1,668)		(1,719)		(5,499)		(5,162)		(12,277)
Total other income (expense)		(1,668)		(1,719)		(5,499)		(5,162)		(12,277)

INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES		32,967		(2,986)		8,525		(10,116)		(118,111)

INCOME TAXES		0		0		0		0		0

INCOME (LOSS) FROM CONTINUING OPERATIONS		32,967		(2,986)		8,525		(10,116)		(118,111)

DISCONTINUED OPERATIONS
Loss from discontinued operations		0		0		0		0		(11,000)

NET INCOME (LOSS)	$	32,967	$	(2,986)	$	8,525	$	(10,116)	$	(129,111)

Basic and diluted net income (loss) per share	$	0.05	$	(0.00)	$	0.01	$	(0.01)

Weighted average shares outstanding		708,000		708,000		708,000		708,000



		FOR THE NINE MONTHS ENDED SEPT 30, 2012		FOR THE NINE MONTHS ENDED SEPT 30, 2011		FROM INCEPTION ON JAN 15, 1988 TO SEPT 30, 2012

Cash Flows from Operating Activities
Net income (loss)	$	8,525	$	(10,116)	$	(129,111)
Adjustments to reconcile net loss to cash used by operating activities:
Shares issued for services		0		0		10,433
Shares issued for debt payment		0		0		1,424
Loss on disposal of property, plant and equipment		0		0		5,263
Changes in assets and liabilities:
Increase in accounts payable and accrued liabilities		16,748		(275)		74,898
Increase in accrued interest		354		5,162		7,132
Net cash used by operating activities		25,627		(5,229)		(29,961)

Cash Flows from Investing Activities
Cash paid for property, plant and equipment		0		0		(5,264)
Net cash used by investing activities		0		0		(5,264)

Cash Flows from Financing Activities
Cash paid for offering costs		0		0		(7,000)
Common stock issued for cash		0		0		21,000
Proceeds from notes payable		10,000		5,000		57,200
Payments on notes payable		(34,855)		0		(34,855)
Net cash provided by financing activities		(24,855)		5,000		36,345

Increase (decrease) in cash		772		(229)		1,120

Cash and cash equivalents at beginning of period		348		1,122		0

Cash and cash equivalents at end of period	$	1,120	$	893	$	1,120

Supplemental Cash Flow Information:
Cash paid for interest	$	0	$	0	$	0
Cash paid for income taxes	$	0	$	0	$	0

Non-Cash Investing and Financing Activities
Converted accounts payable into loans	$	0	$	80,926	$	80,926